These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9484877)

  • 1. Safety profile of grepafloxacin compared with other fluoroquinolones.
    Stahlmann R; Schwabe R
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():83-92. PubMed ID: 9484877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
    Chodosh S; Lakshminarayan S; Swarz H; Breisch S
    Antimicrob Agents Chemother; 1998 Jan; 42(1):114-20. PubMed ID: 9449270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grepafloxacin.
    Wagstaff AJ; Balfour JA
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
    O'Doherty B; Dutchman DA; Pettit R; Maroli A
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
    Topkis S; Swarz H; Breisch SA; Maroli AN
    Clin Ther; 1997; 19(5):975-88. PubMed ID: 9385485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of grepafloxacin.
    Wiedemann B; Heisig P
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():19-25. PubMed ID: 9484869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
    Langan CE; Cranfield R; Breisch S; Pettit R
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():63-72. PubMed ID: 9484875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Grepafloxacin (Vaxar)--innovative antibiotic for therapy of respiratory tract infections. Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. Lausanne/Switzerland, 25 May 1997].
    Pneumologie; 1997 Sep; 51(9 Suppl):1-4. PubMed ID: 9417540
    [No Abstract]   [Full Text] [Related]  

  • 10. Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin.
    Ferguson J; Dawe R
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():93-8. PubMed ID: 9484878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative arthropathy of fluoroquinolones in dogs.
    Takizawa T; Hashimoto K; Minami T; Yamashita S; Owen K
    Hum Exp Toxicol; 1999 Jun; 18(6):392-9. PubMed ID: 10413244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
    Goldstein EJ
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activity of grepafloxacin against respiratory pathogens in the UK.
    Wise R; Andrews JM
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety.
    Geddes AM
    Expert Opin Investig Drugs; 1999 Apr; 8(4):487-505. PubMed ID: 15992094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats.
    Takizawa T; Hasimoto K; Itoh N; Yamashita S; Owen K
    Hum Exp Toxicol; 1999 Jan; 18(1):38-45. PubMed ID: 10025367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
    Lipsky BA; Dorr MB; Magner DJ; Talbot GH
    Clin Ther; 1999 Jan; 21(1):148-59. PubMed ID: 10090432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ
    Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical toxicological aspects of fluoroquinolones.
    Stahlmann R
    Toxicol Lett; 2002 Feb; 127(1-3):269-77. PubMed ID: 12052667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
    Shakibaei M; Baumann-Wilschke I; Rücker M; Stahlmann R
    Arch Toxicol; 2002 Jan; 75(11-12):725-33. PubMed ID: 11876506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.